Re: ZEN-3694 Single Agent Trial Status

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7656 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: ZEN-3694 Single Agent Trial Status

posted on Sep 19, 2017 01:04PM

Three for three in favor of both being taken out in one deal. I would be totally happy to be wrong. Thanks for playing the game.